Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials.
Journal: Transplantation and cellular therapy
Published: May 18, 2025
Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma.
Journal: Blood advances
Published: July 24, 2023
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Journal: Lancet (London, England)
Published: April 18, 2023
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Journal: The Lancet. Oncology
Published: December 14, 2022
Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.
Journal: Cancer journal (Sudbury, Mass.)
Published: March 22, 2021
Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis.
Journal: Transplantation and cellular therapy
Published: February 02, 2021
A clinical perspective on plasma cell leukemia; current status and future directions.
Journal: Blood cancer journal
Published: October 13, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.
Journal: Transplantation and cellular therapy
Published: August 20, 2020
Last Updated: 09/26/2026